Pharmaceuticals, Biotechnology and Life Sciences
Gilead get’s authorization of emergency use of Remdesivir to treat hospitalized patients with severe COVID-19 disease in the United States.
FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies…
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating…
Gilead’s company Kite’s trial for KTE-X19, its chimeric antigen receptor T cell therapy for adults with ALL (leukemia), resulted in…
World’s largest HIV/AIDS drug-maker Mylan has received tentative approval for combination HIV treatment DTG/FTC/TAF under FDA’s PEPFAR program, the company…
ViiV Healthcare on Thursday said it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United…
Gilead Sciences has promoted Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs,…
The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United…
The U.S. Food and Drug Administration on Tuesday approved Gildad’s Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir.
The U.S. Food and Drug Administration has approved the first generic version of Gilead’s Truvada for the treatment of HIV-1, in combination with other antiretroviral agents, and for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to prevent sexually-acquired HIV infection in adults at high risk.